Bestellen Sie jetzt auf

Cansativa Group and Akanda Corp. to Bring New Medical Cannabis Flowers to Germany

9.8.2022 | Frankfurt / London | cansativa
Zurück zur Übersicht

Frankfurt am Main and London, August 9, 2022 – Akanda Corp. ("Akanda") (NASDAQ: AKAN) and Cansativa GmbH (“Cansativa Group”) today jointly announced anew cooperation that will soon allow German pharmacies to provide patients with two novel cannabis cultivars. This collaboration allows the Cansativa platform to supply the German market with dried flowers from Akanda’s EU-GMP certified indoor grow facility in Sintra, Portugal. Akanda is expected to deliver at least 1,000 kilograms to Cansativa over the first 12-month term of the agreement.

“We are very glad about this agreement that allows us to introduce two novel medical cannabis flowers to the German market. This enables patient access to an additional supplier with a new and innovative range of medical products. This exciting cooperation marks another step in improving the product diversity and security of supply on theGerman market.We look forward to a long-term relationship with Akanda, with whom we share an important part of our mission: We want to enable physicians, pharmacies, and patients by giving them access to an extensive medical product portfolio and help improve the quality of life with the help of medical cannabis”,says Benedikt Sons, co-founder and CEO of the Cansativa Group.

“Our prized purpose-built indoor grow facility in Portugal is the only one of its kind that can produce EU-GMP medical cannabis equivalent to the adult-usegrades available in North America. It has both the quality and scalability to meet the growing demand for medical cannabis in fast-growing markets across the EMEA region, such as Germany. We are equally excited to be partnering with the Cansativa Group to bring some of our best strains to Germany through their platform. This supply agreement represents one of the largest agreements in the nascent European medical cannabis industry and is certainly Akanda’s most substantial commercial development to date, enabling new patient experience,” affirms Tej Virk, CEO of Akanda.

All pharmacies in Germany will be able to purchase these products through the Cansativa platform.

About Cansativa Group

Cansativa Group is the German leader in the medical cannabis market and sees itself as the driving force of the cannabis industry in Germany. Since the award of the Federal Institute for Drugs and Medical Devices (BfArM) in August 2020, theyarethe only company with approval for the distribution of medical cannabis from German cultivation. In the upcoming cannabis legalization, the Cansativa Group sees itself as a pioneer of the democratizationof the cannabis market. Theyimport, store, license, distribute, supply, brand and educate.

Connect with Cansativa Group: Website| LinkedIn

About Akanda Corp.

Akanda is an international medical cannabis and wellness platform company seeking to help people lead better lives through improved access to high quality and affordable products. Akanda’s portfolio includes Holigen, a Portugal-based cultivator, manufacturer and distributor with a prized EU GMP certified indoor grow facility; Bophelo Bioscience & Wellness, a GACP qualified cultivation campus in the Kingdom of Lesotho in Southern Africa; and CanMart, a UK-based fully licensed pharmaceutical importer and distributor which supplies pharmacies and clinics within the UK. The Company’s seed-to-patient supply chain also includes partnerships with Cellen Life Sciences’ Leva Clinic, one of the first fully digital pain clinics in the UK.

Connect with Akanda: Website|LinkedIn|Twitter|Instagram


Cansativa Press Contact:

Akanda Investor Contact:

Matt Chesler, CFA


Akanda Press Contact:

Imogen Saunders

Irvine Partners

Zurück zur Übersicht
15.12.2022 | Frankfurt / Mörfelden

AMICI takes the next step – leading the premium medical cannabis market with new THC levels.

After launching a new premium medical cannabis brand under the name “AMICI” in Mid-November, Cansativa Group, Germany’s leading cannabis platform, now closes the year of 2022 with a new high THC product, which sets itself at the top of the medical cannabis market. The previously launched product line consists of the two types “Strawberry Banana” and “Cherry Pie” and features high microbiological purity beside particular product details, which have been tested by experts and patients in the last weeks.
30.11.2022 | Frankfurt / Mörfelden

Die G-BA Änderungen der Arzneimittel-Richtlinien führen zu großen Risiken..

Ausgangslage: Die Handhabe von Cannabis als Medizin steht auf dem Prüfstand. Seit dem Inkrafttreten des „Gesetzes zur Änderung betäubungsmittelrechtlicher und anderer Vorschriften“ im März 2017 dürfen Cannabisarzneimitteln als Therapiealternative verordnet werden. Seit dem Inkrafttreten des „Gesetzes zur Änderung betäubungsmittelrechtlicher und anderer Vorschriften“ im März 2017 dürfen Cannabisarzneimitteln als Therapiealternative verordnet werden. Die Verantwortung hierfür wurde im selben Jahr in die Hände der behandelnden Ärzt:innen gelegt. Die Kosten, die für Patient:innen im Rahmen der Behandlung entstehen, wurden hierbei –bei vorheriger Kostenübernahmegenehmigung –durch die gesetzliche Krankenversicherung übernommen.
9.11.2022 | Frankfurt / Mörfelden

AMICI - Premium medical cannabis enabled by Cansativa

The Cansativa Group, Germany's leading cannabis platform, is launching a new premium medical cannabis brand under the name "AMICI". This new product line consists of the two products, „Strawberry Banana" and "Cherry Pie", which have a high microbiological purity. All products ofthe brand "AMICI" are unirradiated. The cultivars derive from strictly EU-GMP controlled indoorcultivation facilities with many years of experience. The addition of "AMICI" to the productportfolio is another milestone and important step for Cansativa.